299 related articles for article (PubMed ID: 31876436)
21. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells.
Chiang ZC; Chiu YK; Lee CC; Hsu NS; Tsou YL; Chen HS; Hsu HR; Yang TJ; Yang AS; Wang AH
PLoS One; 2020; 15(9):e0239813. PubMed ID: 32986768
[TBL] [Abstract][Full Text] [Related]
22. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Clardy SM; Uttard A; Du B; Catcott KC; Lancaster KL; Ditty E; Sadowsky J; Zurita J; Malli N; Qin L; Bradley SP; Avocetien K; Carter T; Kim D; Nazzaro M; Xu L; Pillow TH; Zacharias NT; Lewis GD; Rowntree RK; Iyengar R; Lee DH; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Jan; 23(1):84-91. PubMed ID: 37774393
[TBL] [Abstract][Full Text] [Related]
23. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
24. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
25. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
26. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
27. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
28. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
[TBL] [Abstract][Full Text] [Related]
29. High-throughput oxidation screen of antibody-drug conjugates by analytical protein A chromatography following IdeS digest.
Buecheler JW; Winzer M; Weber C; Gieseler H
J Pharm Pharmacol; 2018 May; 70(5):625-635. PubMed ID: 29380379
[TBL] [Abstract][Full Text] [Related]
30. Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones.
Bahou C; Richards DA; Maruani A; Love EA; Javaid F; Caddick S; Baker JR; Chudasama V
Org Biomol Chem; 2018 Feb; 16(8):1359-1366. PubMed ID: 29405223
[TBL] [Abstract][Full Text] [Related]
31. Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates.
Gandhi AV; Arlotta KJ; Chen HN; Owen SC; Carpenter JF
J Pharm Sci; 2018 Jul; 107(7):1858-1869. PubMed ID: 29626535
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.
Axup JY; Bajjuri KM; Ritland M; Hutchins BM; Kim CH; Kazane SA; Halder R; Forsyth JS; Santidrian AF; Stafin K; Lu Y; Tran H; Seller AJ; Biroc SL; Szydlik A; Pinkstaff JK; Tian F; Sinha SC; Felding-Habermann B; Smider VV; Schultz PG
Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16101-6. PubMed ID: 22988081
[TBL] [Abstract][Full Text] [Related]
33. Conjugation Site Analysis of Lysine-Conjugated ADCs.
Sang H; Wan N; Lu G; Tian Y; Wang G; Ye H
Methods Mol Biol; 2020; 2078():235-250. PubMed ID: 31643061
[TBL] [Abstract][Full Text] [Related]
34. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.
Cao M; De Mel N; Jiao Y; Howard J; Parthemore C; Korman S; Thompson C; Wendeler M; Liu D
MAbs; 2019; 11(6):1064-1076. PubMed ID: 31198090
[TBL] [Abstract][Full Text] [Related]
35. Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.
Buecheler JW; Winzer M; Tonillo J; Weber C; Gieseler H
Mol Pharm; 2018 Jul; 15(7):2656-2664. PubMed ID: 29809017
[TBL] [Abstract][Full Text] [Related]
36. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
37. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.
Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G
MAbs; 2018; 10(4):583-595. PubMed ID: 29436897
[TBL] [Abstract][Full Text] [Related]
38. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
[TBL] [Abstract][Full Text] [Related]
39. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
40. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
